Community post

Huge milestone alert! BiomX has announced successful Phase II clinical trial results for their BX211 phage product against diabetic foot osteomyelitis!

Subscribe to the Podovirus podcast to learn more — we'll be interviewing BiomX CEO Jonathan Solomon later this month!